- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
GE HealthCare Unveils Head-Only MRI Device at ISMRM Conference
For neuroradiologists, the Signa Magnus 3T MRI system may offer enhanced visualization of the brain microstructure, microvasculature, and function.
Offering a combination of advanced gradient technology, deep-learning algorithms and short echo times, GE HealthCare is showcasing the new Signa Magnus 3T MRI at the International Society for Magnetic Resonance in Medicine (ISMRM) Annual Meeting in Singapore, Asia.
Featuring a gradient strength of 300 mT/m and slew rate of 750 T/m/s, the Signa Magnus is dedicated to head-only MRI imaging and reportedly provides enhanced imaging detail of the brain’s function, microstructure, and microvasculature, according to GE HealthCare.
Reportedly offering enhanced imaging detail of the brain’s function, microstructure, and microvasculature, the head-only 3T MRI system Signa Magnus provides higher b-value diffusion with short echo times, according to GE HealthCare, the manufacturer of the device. (Photo courtesy of GE HealthCare.)
In addition to deep-learning algorithms to bolster advanced imaging techniques, the company said another key attribute of the Signa Magnus MRI system is the capability to achieve higher b-value diffusion with short echo times.
"With Signa Magnus, we are not just exploring the possibility of providing the tool; we are setting new benchmarks in medical research and future clinical patient care.” said Kelly Londy, the chief executive officer of MR for GE HealthCare. “This innovation underscores our commitment to R&D and our collaborations with academia, pushing the boundaries of what's possible in MR imaging. The potential impact of Signa Magnus on patient outcomes and our understanding of the human brain is profound."
GE HealthCare noted that the Signa Magnus system is pending 510(k) clearance from the Food and Drug Administration (FDA).
Leading Breast Radiologists Discuss the USPSTF Breast Cancer Screening Recommendations
May 17th 2024In recognition of National Women’s Health Week, Dana Bonaminio, MD, Amy Patel, MD, and Stacy Smith-Foley, MD, shared their thoughts and perspectives on the recently updated breast cancer screening recommendations from the United States Preventive Services Task Force (USPSTF).
Current Insights and Emerging Roles for Contrast-Enhanced Mammography
May 10th 2024In a recent lecture at the 2024 ARRS Annual Meeting, Jordana Phillips, MD, discussed the role of contrast-enhanced mammography in staging breast cancer, evaluating response to neoadjuvant chemotherapy and recalls from screening.
MRI-Based Deep Learning Algorithm Shows Comparable Detection of csPCa to Radiologists
May 8th 2024In a study involving over 1,000 visible prostate lesions on biparametric MRI, a deep learning algorithm detected 96 percent of clinically significant prostate cancer (csPCa) in comparison to a 98 percent detection rate for an expert genitourinary radiologist.
